Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02255552 · ClinicalTrials.gov registry record · Phase 3
Study of Eteplirsen in DMD Patients
A Phase 3 study, sponsored by Sarepta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 109
- Enrollment target
NCT02255552 is a Phase 3 study that has completed, run by Sarepta Therapeutics. The registered enrollment target is 109 participants.
The verdict
NCT02255552, a Phase 3 study, has completed, sponsored by Sarepta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 109 participants
- Enrollment target
Study Summary
The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).
Interventions
- DRUG eteplirsen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02255552
The ClinicalTrials.gov registry entry for NCT02255552 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sarepta Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eteplirsen is the first listed.
NCT02255552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02255552 about?
NCT02255552 is a clinical study titled "Study of Eteplirsen in DMD Patients". The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, fol...
What is the current status of trial NCT02255552?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 109 participants. The study started on 2014-11-17. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT02255552?
The interventions under investigation include: eteplirsen (DRUG).
Who is sponsoring clinical trial NCT02255552?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.